AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Polyacrylamide gel electrophoresis (PAGE) is used for separating proteins ranging in size from 5 to 2,000 kDa due to the uniform pore size provided by the polyacrylamide gel. Pore size is controlled by modulating the concentrations of acrylamide and bis-acrylamide powder and by the polymerization time used in creating a gel. Care must be used when creating this type of gel, as acrylamide is a potent neurotoxin in its liquid and powdered forms. Traditional DNA sequencing techniques such as Maxam-Gilbert or Sanger methods used polyacrylamide gels to separate DNA fragments differing by a single base-pair in length so the sequence could be read. Most modern DNA separation methods now use agarose gels, except for particularly small DNA fragments. It is currently most often used in the field of immunology and protein analysis, often used to separate different proteins or isoforms of the same protein into separate bands. These can be transferred onto a nitrocellulose or PVDF membrane to be probed with antibodies and corresponding markers, such as in a western blot. Typically resolving gels are made in 4%, 6%, 8%, 10%, 12% or 15% T. Stacking gel (5% T) is poured on top of the resolving gel and a gel comb (which forms the wells and defines the lanes where proteins, sample buffer, and ladders will be placed) is inserted. The percentage chosen depends on the size of the protein that one wishes to identify or probe in the sample. The smaller the known weight, the higher the percentage that should be used.
==== Solute Properties ==== When solutes are added to a solvent, they change the solution's optical density. The size, polarizability and shape and molecular structure of a solute all have effects on the refractive index of a solution. Generally, a Gaussian distribution is observed, although deviations occur.
The day after the former Federal Reserve chairs and Treasury Secretaries issued their joint statement, European Central Bank (ECB) President Christine Lagarde, Bank of England Governor Andrew Bailey, and the executives of the central banks of Canada, Sweden, Denmark, Switzerland, Australia, South Korea, Brazil, and France also issued a joint public statement in defense of Powell that stated: "The independence of central banks is a cornerstone of price, financial and economic stability in the interest of the citizens that we serve. It is therefore critical to preserve that independence, with full respect for the rule of law and democratic accountability." Bank of Japan Governor Kazuo Ueda reportedly did not sign the joint statement led by Lagarde and Bailey due to not receiving informal approval from the government of Prime Minister Sanae Takaichi in time for the statement's release. Bank of Latvia Governor Mārtiņš Kazāks and former ECB President and Bank of France Governor Jean-Claude Trichet likewise argued that Powell's investigation was comparable to the conduct of monetary policy in emerging markets but that could threaten the stability of the global financial system, while Bank of Finland Governor Olli Rehn warned of a structural rise in the global inflation rate if the Federal Reserve's independence were to be compromised that would likely require monetary policy decisions globally to protect price stability and general economic stability.
Sources: en.wikipedia.org
=== PT Prachuap === Townsend left Kanchanaburi following their relegation from the top flight and joined fellow Thai club PT Prachuap in August 2026. In September 2026, Townsend was run over by a pitch roller during warmup for a league match, in what has been described as "a bizarre incident". He reportedly avoided serious injury.
=== Immunoglobulins, complement and fibrinogen === Immunoglobulins (IgM, IgA), complement (C3), and fibrinogen have been found in blood vessel walls of patients with NL. Both Immunoglobulin and C3 are known to play a significant role in the immune response. Fibrinogen is a protein that plays a crucial role in blood clotting (often found at the dermal-epidermal junction). These deposits cause vascular thickening, which is a hallmark of NL.
Rubidium chloride (RbCl) is probably the most used rubidium compound: among several other chlorides, it is used to induce living cells to take up DNA; it is also used as a biomarker, because in nature, it is found only in small quantities in living organisms and when present, replaces potassium. Other common rubidium compounds are the corrosive rubidium hydroxide (RbOH), the starting material for most rubidium-based chemical processes; rubidium carbonate (Rb2CO3), used in some optical glasses, and rubidium copper sulfate, Rb2SO4·CuSO4·6H2O. Rubidium silver iodide (RbAg4I5) has the highest room temperature conductivity of any known ionic crystal, a property exploited in thin film batteries and other applications. Rubidium forms a number of oxides when exposed to air, including rubidium monoxide (Rb2O), Rb6O, and Rb9O2; rubidium in excess oxygen gives the superoxide RbO2. Rubidium forms salts with halogens, producing rubidium fluoride, rubidium chloride, rubidium bromide, and rubidium iodide.
Iranian officials described the attack as an attempt to derail diplomacy, noting that Kharazi was overseeing a possible meeting between Iranian officials and US vice president JD Vance. Airstrikes on the strategically important Hengam Island in the Strait of Hormuz caused seven injuries. Netanyahu asserted that the US–Israeli strikes have eliminated Iran's ability to produce nuclear weapons and ballistic missiles, thereby removing "two existential threats" to Israel. Late in the day on 1 April, Trump made a speech addressing the nation, in which he said that the strikes have "dramatically curtailed" Iranian missile and drone systems, and added that the attacks on Iran will escalate over the next two to three weeks to "bring them back to the Stone Ages, where they belong". On 2 April, two US strikes on the B1 bridge between Tehran and Karaj, which was described as the highest bridge in the Middle East, reportedly killed eight people and wounded 95 others, causing it to collapse. Experts assessed the attack as a possible war crime; it was celebrated by Trump. At the time of the attack, many Iranian families had been gathered in the parks below the bridge to celebrate Sizdah Be-dar. Iran revealed major damage to the century-old medical center Pasteur Institute of Iran. US defense secretary Hegseth boasted of "death and destruction from the sky all day long". The IDF also announced that one of its strikes in the Kermanshah area of Iran killed Iranian ballistics missile chief Makram Atimi and several battalion commanders from Atimi's central Iranian ballistic missile unit.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.